Biblioteca de Estudios Científicos sobre Microdosificación con Psilocibina
Esta web es una recopilación de enlaces a investigaciones científicas que están validando la microdosificación con psilocibina. Recursos del libro.
¨
Estudio [1] — Daños de las drogas en el Reino Unido
[1] Nutt, D. J., et al.
"Drug harms in the UK: a multicriteria decision analysis". The Lancet.
Estudios [2]–[6] — Neuroplasticidad y Psicodélicos
[2] Vargas, M. V., et al. (2023)
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Publicado en Science, 379(6633), 700-706.
[3] Brewer, J. A., et al. (2011)
Meditation experience is associated with differences in default mode network activity and connectivity. Proceedings of the National Academy of Sciences (PNAS), 108(50), 20254-20259.
[4] Johnson, M. W., Griffiths, R. R., & Hendricks, P. S. (2018)
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 142, 143-166.
[5] Calder, A. E., & Hasler, G. (2023)
Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology (Nature), 48(1), 104-112.
[6] de Vos, C. M. H., et al. (2021)
Psychedelics and Neuroplasticity: A Systematic Review. Frontiers in Psychiatry, 12, 724606.
Estudios [7]–[8] — Integración y Desincronización Cerebral
[7] Daws, R. E., et al. (2022)
Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine, 28(4), 844-851. Basado en la investigación de la UCSF.
[8] Siegel, J. S., et al. (2024)
Psilocybin desynchronizes the human brain. Nature, 632(8023), 131-138.
Estudios [9]–[11] — Microdosificación: Ansiedad, Estado de Ánimo y Beneficios
1
[9] Rootman, J. M., et al. (2021)
Adults who microdose psychedelics report lower levels of anxiety and depression. Scientific Reports, 11(1), 22479.
2
[10] Rootman, J. M., et al. (2022)
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. Scientific Reports, 12(1), 11035.
3
[11] Anderson, T., et al. (2020)
Psychedelic microdosing benefits and challenges: an empirical codebook. Journal of Psychoactive Drugs, 51(2), 173-194.
Estudios [12]–[15] — OCD, Cuidados Paliativos y Contextos Culturales
[12] Moreno, F. A., et al. (2025)
Single-dose (10 mg) psilocybin reduces symptoms in adults with OCD. Journal of Affective Disorders / ScienceDirect.
[13] Sager, P. R., Sager, V. S., & Gupta, A. (2023)
Psilocybin in Palliative Care: An Update. Current Geriatrics Reports, 12(3), 115-123.
[14] Guendelman, R., Garay, G., & Ivulic, M. M. (2014)
Neurociencias y aplicaciones psicoterapéuticas en el renacimiento de la investigación con psicodélicos. Revista Chilena de Neuro-psiquiatría, 52(2), 112-121.
[15] Pérez, E. A. (2014)
La modulación del estado de conciencia en rituales con empleo de plantas psicoactivas: el caso del peyote y los hongos psilocybe. Tesis de Licenciatura en Antropología Social, UAEM.
Estudios [16]–[20] — Longevidad, Potencial Terapéutico y Efecto Séquito
[16] Shen, H. G., Wang, J., et al. (2025)
Psilocybin treatment extends cellular lifespan and improves survival. npj Aging, 11(1), 5.
[17] Lowe, H., Toyang, N., et al. (2021)
The Therapeutic Potential of Psilocybin: A Systematic Review. Molecules, 26(10), 2948.
[18] Nayak, S. J., & Griffiths, R. R. (2022)
A Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depression: Impact on Patient-Reported Outcomes and Practical Considerations. Frontiers in Psychiatry, 13, 1040217.
[19] Emory University (2025)
Psilocybin delays aging, extends lifespan in new study. Emory Health Sciences.
[20] Murray, Z., et al. (2026)
Network pharmacology and molecular simulation reveal the mechanisms of the entourage effect of psilocybin-producing mushrooms in the brain. Scientific Reports.